Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
The Fabricator21h
Lexicon Inc. names director of HR shared services
Lexicon Inc., based in Little Rock, Ark., has promoted Brandy Thomas to director of HR shared services.
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.
Houston-area company may be developing next hot weight-loss drug
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
Fierce Biotech7d
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...
The Woodlands-based company strikes obesity-drug license deal worth up to $1B
Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual ...
American Association of Individual Investors4d
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Down 25.32%
Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 25.32%, which has investors questioning if this is right time to buy.
American Association of Individual Investors7d
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Up 77.50%
Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 77.50%, which has investors questioning if this is right time ...
What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals
In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average ...
Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal
Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.